$0.77
1.01% yesterday
Nasdaq, Jun 25, 10:02 pm CET
ISIN
US0198181036
Symbol
ALVR

AlloVir Inc Share price

$0.77
+0.02 1.98% 1M
+0.01 0.86% 6M
+0.09 13.56% YTD
-2.51 76.46% 1Y
-20.40 96.35% 3Y
-24.62 96.96% 5Y
-24.62 96.96% 10Y
Nasdaq, Closing price Tue, Jun 25 2024
ISIN
US0198181036
Symbol
ALVR
Sector
Industry

Key figures

Market capitalization $88.78m
Enterprise Value $-33.41m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.24
P/B ratio (TTM) P/B ratio 0.74
Turnover (TTM) Turnover $0.00
EBIT (operating result TTM) EBIT $-160.94m
Free cash flow (TTM) Free cash flow $-136.71m
Cash position $140.53m
EPS (TTM) EPS $-1.66
P/E ratio expected negative
Short interest 10.25%
Show more

Is AlloVir Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,951 shares worldwide.

AlloVir Inc Share analysis

Unlock scores for free

Analyst opinions

4 Analysts have issued a AlloVir Inc forecast:

1x Hold
25%
3x Sell
75%

Analyst opinions

4 Analysts have issued a AlloVir Inc forecast:

Hold
25%
Sell
75%

Financial data from AlloVir Inc

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
- -
-
100%
- Direct costs 3.78 3.78
67% 67%
-
- -
-
-
- Selling and administrative expenses 46 46
4% 4%
-
- Research and development costs 111 111
6% 6%
-
-161 -161
5% 5%
-
- Depreciation and amortization - -
-
-
EBIT (operating result) EBIT -161 -161
6% 6%
-
Net profit -180 -180
8% 8%
-

Figures in millions USD.

Don't miss a thing! We will send you all news about the AlloVir Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

AlloVir Inc Share News

Neutral
Accesswire
3 months ago
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71800&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
3 months ago
NEW YORK , March 19, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR). The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv-10152, is on behalf of a class consisting of all persons and entities other than Defendants that purc...
Neutral
Accesswire
3 months ago
NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71751&wire=1 or contact Joseph E. Levi, Esq.
More AlloVir Inc News

Company profile

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.

Head office United States
CEO Diana Brainard
Employees 112
Founded 2013
Website www.allovir.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now